MC
CATX icon

Moors & Cabot’s Perspective Therapeutics CATX Stock Holding History

Moors & Cabot’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$5K – 786
2020
Q4 		$5K Hold
1,000
– – ﹤0.01% 728
2020
Q3 		$6K Hold
1,000
– – ﹤0.01% 692
2020
Q2 		$6K Hold
1,000
– – ﹤0.01% 658
2020
Q1 		$5K Hold
1,000
– – ﹤0.01% 583
2019
Q4 		$6K Hold
1,000
– – ﹤0.01% 610
2019
Q3 		$3K Hold
1,000
– – ﹤0.01% 661
2019
Q2 		$4K Hold
1,000
– – ﹤0.01% 548
2019
Q1 		$4K Buy
+1,000
New +$3.9K ﹤0.01% 524

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HPWM
Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Moors & Cabot's CATX Position: Q1 2021 in Review

Moors & Cabot sold out of Perspective Therapeutics (CATX) in Q1 2021, closing a stake of 1,000 shares — an estimated $5K sold.

Moors & Cabot first reported a position in CATX in Q1 2019 and held it in 8 quarters. The position peaked at $6K in Q3 2020. 57 funds tracked by Wall St. Rank hold CATX as of Q1 2021.

  • Moors & Cabot reported no remaining Perspective Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Moors & Cabot sold 1,000 Perspective Therapeutics shares in Q1 2021, an estimated $5K.
  • Moors & Cabot first reported a position in Perspective Therapeutics in Q1 2019 and held it in 8 quarters.
  • Moors & Cabot's Perspective Therapeutics position peaked at $6K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2021.

Based on Moors & Cabot's 13F filing for Q1 2021, filed 12 May 2021.